Table 1.
Cohort Demographics and Outcomes According to TMP-SMX Exposure
| Characteristic | TMP-SMX Exposed (n = 12064) | TMP-SMX Unexposed (n = 107335) |
|---|---|---|
| Baseline age | ||
| Median (IQR) (y) | 2.5 (0–9) | 3 (0–9) |
| Range (mo) | 0–18 | 0–18 |
| Sex, female (n [%]) | 5782 (48) | 41561 (39) |
| Race (n [%]) | ||
| White | 9142 (76) | 78637 (73) |
| Black | 1375 (11) | 11850 (11) |
| Hispanic | 1250 (10) | 12901 (12) |
| Asian | 297 (2) | 3950 (4) |
| Geographic region (n [%])a | ||
| 1 | 724 (6) | 11944 (11) |
| 2 | 3047 (25) | 30644 (29) |
| 3 | 7331 (61) | 53830 (50) |
| 4 | 962 (8) | 10920 (10) |
| Cohort time | ||
| Median (IQR) (mo) | 12 (7–20) | 8 (5–13) |
| Range (mo) | 1–133 | 1–143 |
| Glucocorticoid exposure | ||
| Median (IQR) (mo) | 10 (6–16) | 6 (4–11) |
| Range (mo) | 1–131 | 1–140 |
| Hospitalization time | ||
| Median (IQR) (mo) | 1 (1–1) | 1 (1–1) |
| Range (mo) | 1–5 | 1–5 |
| TMP-SMX exposure | ||
| Median (IQR) (mo) | 3 (2–4) | N/A |
| Range (mo) | 1–82 | N/A |
| Additional immunosuppressant exposure | ||
| Median (IQR) (mo) | 10 (5–19) | 8 (5–14) |
| Range (mo) | 1–82 | 1–81 |
Abbreviations: IQR, interquartile range; N/A, not applicable; TMP-SMX, trimethoprim-sulfamethoxazole.
aRegions according to the US Census: Region 1, CT, MA, ME, NH, NJ, NY, PA, RI, and VT; region 2, IA, IL, IN, KS, MI, MN, MO, NE, ND, OH, SD, and WI; Region 3, AL, AR, DE, DC, FL, GA, KY, LA, MD, MS, NC, OK, SC, TN, TX, and VA; and Region 4, AK, AZ, CA, CO, HI, ID, MT, NM, NV, OR, WA, and WY.